Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
As a diverse meeting of multidisciplinary experts, the annual ELCC provides a collaborative forum for discussing advances in clinical research and communicating practice-changing data in thoracic oncology.
At the congress, Boehringer Ingelheim will be hosting a symposium as well as presenting data highlighting recent findings in the treatment of lung cancer. Please see below for more information, and revisit this page for further details nearer the event.
Join us at our ELCC symposium to hear a faculty of renowned experts discuss the sequence of treatment in EGFR-mutation positive NSCLC and in non-mutated, non-squamous advanced NSCLC, and pose your questions on these topics.
IRCCS San Raffaele Hospital, Milan
Thorax Institute Curie-Montsouris
Lung Clinic Grosshansdorf
Come and find out more about our emerging data during the scientific programme at ELCC.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: February 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue